Sabby Management’s Titan Pharmaceuticals TTNP Stock Holding History

Sabby Management’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,095	Closed	-$803K	–	149
2020 Q3	$803K	Buy	+8,095	New	+$1.25M	0.12%	69
2019 Q4	–	Sell	-139	Closed	-$22K	–	87
2019 Q3	$22K	Buy	+139	New	+$62.7K	0.01%	89
2018 Q4	–	Sell	-422	Closed	-$314K	–	142
2018 Q3	$314K	Buy	+422	New	+$1.15M	0.04%	86

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $75.9M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Sabby Management's TTNP Position: Q4 2020 in Review

Sabby Management sold out of Titan Pharmaceuticals (TTNP) in Q4 2020, closing a stake of 8,095 shares — an estimated $803K sold.

Sabby Management first reported a position in TTNP in Q3 2018 and held it in 3 quarters. The position peaked at $803K in Q3 2020. 15 funds tracked by Wall St. Rank hold TTNP as of Q4 2020.

Sabby Management reported no remaining Titan Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sabby Management sold 8,095 Titan Pharmaceuticals shares in Q4 2020, an estimated $803K.
Sabby Management first reported a position in Titan Pharmaceuticals in Q3 2018 and held it in 3 quarters.
Sabby Management's Titan Pharmaceuticals position peaked at $803K in Q3 2020.
15 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.